Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc.（VVOS）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · VVOS · 截至 2025年9月30日
股东结构概览
22
机构持有人数
▲ 4 vs Q2
$2.13M
机构持仓总市值
▲ $857,977 vs Q2
5.89M
总流通股
freeFloat 54.21%
686,727
13F 申报持股数
▲ 284,645 vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
VVOS 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
CONNECTIVE CAPITAL MANAGEMENT, LLC surgical & medical instruments & apparatus | 200.0K | 2.20% | 2.20% | $620.00M | Nov 17, 2025 | NEW |
STRATEGIC WEALTH INVESTMENT GROUP, LLC surgical & medical instruments & apparatus | 100.0K | 1.10% | 1.10% | $310.00M | Nov 14, 2025 | NEW |
VANGUARD GROUP INC surgical & medical instruments & apparatus | 91.5K | 1.01% | 1.01% | $283.53M | Nov 7, 2025 | ▲ 48.8K |
GEODE CAPITAL MANAGEMENT, LLC surgical & medical instruments & apparatus | 53.3K | 58.64% | 58.64% | $165.19M | Nov 12, 2025 | ▼ 4.6K |
B. RILEY WEALTH ADVISORS, INC. surgical & medical instruments & apparatus | 43.5K | 47.90% | 47.90% | $134.95M | Oct 31, 2025 | ▼ 26.0K |
DRW SECURITIES, LLC surgical & medical instruments & apparatus | 41.5K | 45.63% | 45.63% | $128.54M | Nov 14, 2025 | NEW |
COMMONWEALTH EQUITY SERVICES, LLC surgical & medical instruments & apparatus | 41.0K | 45.12% | 45.12% | $127.00M | Oct 22, 2025 | — held |
RENAISSANCE TECHNOLOGIES LLC surgical & medical instruments & apparatus | 39.3K | 43.22% | 43.22% | $121.77M | Nov 13, 2025 | NEW |
BLACKROCK, INC. surgical & medical instruments & apparatus | 27.8K | 30.61% | 30.61% | $86.23M | Nov 12, 2025 | NEW |
STATE STREET CORP surgical & medical instruments & apparatus | 24.9K | 27.43% | 27.43% | $77.26M | Nov 14, 2025 | ▲ 13.1K |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
4
增持
+70.0K 股7
新建仓
首次建仓4
减持
−173.3K 股3
清仓
完全退出净股数变化（前50家）
103.3K
+70.0K / −173.3K
净新增持仓人
+4
新建 7 个 / 退出 3 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
VVOS 内幕交易记录
数据来源：SEC Form 4
近期内部人员净买入。 卖出可能源于预定的 10b5-1 计划，不代表负面展望。
5
买入笔数
0
卖出笔数
0.00
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Skaff Michael C 10 percent owner | Mar 31, 2026 | Purchase | 1,783,582 | $1.09 | $1.94M | 1.78M | Form 4 ↗ |
Skaff Michael C 10 percent owner | Mar 31, 2026 | Purchase | 1,783,582 | $1.09 | $1.94M | 1.78M | Form 4 ↗ |
Skaff Michael C 10 percent owner | Mar 31, 2026 | Purchase | 308,848 | $1.34 | $413.9K | 1.35M | Form 4 ↗ |
Skaff Michael C 10 percent owner | Mar 31, 2026 | Purchase | 1,044,777 | $1.34 | $1.40M | 1.04M | Form 4 ↗ |
Skaff Michael C 10 percent owner | Mar 31, 2026 | Purchase | 429,957 | $0.00 | $42.996 | 430.0K | Form 4 ↗ |
Huntsman Ronald Kirk Chief Executive Officer | Nov 26, 2024 | Award | 315,421 | $2.64 | $832.7K | 364.8K | Form 4 ↗ |
Amman Bradford K. Chief Financial Officer | Nov 26, 2024 | Award | 149,533 | $2.64 | $394.8K | 180.5K | Form 4 ↗ |
Huntsman Ronald Kirk Chief Executive Officer | Jun 20, 2024 | Award | 20,000 | $2.38 | $47.6K | 49.3K | Form 4 ↗ |
SOKOLOW LEONARD J director | Jun 20, 2024 | Award | 4,000 | $2.38 | $9.5K | 7.5K | Form 4 ↗ |
Thompson Matthew director | Jun 20, 2024 | Award | 4,000 | $2.38 | $9.5K | 7.1K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Vivos Therapeutics, Inc.（VVOS）主要由机构投资者持有，机构持股比例约为 11.7%。公司内部人员持股约 45.79%，散户及公众持股约占剩余的 42.55%。
Vivos Therapeutics, Inc. 最大机构股东为 CONNECTIVE CAPITAL MANAGEMENT, LLC，截至 September 30, 2025 持有约 200,000 股，占总流通股的 2.20%。
目前共有 22 家机构持有 VVOS 股票，合计持仓市值约 $2,129,135，数据来源为最新 SEC 13F 申报。
常见问题
VVOS ownershipVivos Therapeutics, Inc.（VVOS）主要由机构投资者持有，机构持股约 11.7%。最大股东为 CONNECTIVE CAPITAL MANAGEMENT, LLC，持股比例 2.20%。内部人员持股约 45.79%。数据来源 SEC Form 13F，截至 September 30, 2025。